| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/20/2004 | US20040096916 Using peptides and aberrant cell surface proteins for diagnosis, prognosis and identification of subtpyes of kidney cell tumors |
| 05/20/2004 | US20040096913 Cloning and expression of a new MCP receptor in glial cells |
| 05/20/2004 | US20040096898 Caloxins |
| 05/20/2004 | US20040096894 Three dimensional structure of cell surface glycoprotein for screening and designing drugs for treatment of inflammation |
| 05/20/2004 | US20040096890 Compositions, organisms and methodologies employing a novel human kinase |
| 05/20/2004 | US20040096888 Comprises nucleotide sequences coding cyclin dependent kinase (PELOTA) for diagnosis, treatment, prognosis and prevention of cell proliferative, cardoivascular, inflammatory, arthritic disorders |
| 05/20/2004 | US20040096882 For injectable solutions; MRNA translation/degradation control |
| 05/20/2004 | US20040096881 For prophylactics/diagnostics/therapeutics; endothelial nitric oxide synthase (eNOS) |
| 05/20/2004 | US20040096877 For diagnosis/treatment/prevention of inflammation/asthma/ allergies |
| 05/20/2004 | US20040096869 For protection of cells against damage/death which characterize stroke, myocardial infarction, Parkinson's disease, Alzheimer's disease, multiple sclerosis, and arthritis |
| 05/20/2004 | US20040096868 For diagnosis/treatment of cancer; drugs; kits; cell-free analysis; solid phase synthesis |
| 05/20/2004 | US20040096858 For diagnosing/treating/preventing genetic/cardiovascular/ vision/reproductive/smooth muscle disorders; polymerase chain reaction (PCR); genetic engineering |
| 05/20/2004 | US20040096848 Oligomeric compounds for the modulation HIF-1alpha expression |
| 05/20/2004 | US20040096847 Regulation of human secretin receptor-like gpcr |
| 05/20/2004 | US20040096842 Molecules involved in the regulation of insulin resistance syndrome (irs) |
| 05/20/2004 | US20040096841 Novel polypeptide-phosphatidic acid phsphatase 29.81 and the polynucleotide encoding said polypeptide |
| 05/20/2004 | US20040096836 For diagnosis/prophylaxis/treatment of inflammation; kits |
| 05/20/2004 | US20040096830 Modulation of protein kinase D2 expression |
| 05/20/2004 | US20040096820 For diagnostic/prognostic/therapeutic agents; identifies polypeptide biomarkers of disease by comparative protein profiling; solid phase synthesis |
| 05/20/2004 | US20040096523 Reduces ability of mammal's leukocytes or platelets to become activated; administering potentiating compound; preventing nonpulmonary ischemia- reperfusion injury |
| 05/20/2004 | US20040096518 Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds |
| 05/20/2004 | US20040096467 Drug, in particular for modulating the immunological response for the control of viruses, tumors, bacteria and parasites |
| 05/20/2004 | US20040096459 Polypeptides to be administered especially to humans and in particular for therapeutic use. The polypeptide to elicit an immune response upon administration to the human subject. |
| 05/20/2004 | US20040096456 Isolated and purified peptides and variants thereof, as well as DNA encoding those peptides, useful to prevent or treat antibody inhibitors of factor VIII |
| 05/20/2004 | US20040096450 Determining the prophylactic suitability and quality control of compositions, such as intravenous immunoglobulin mixtures and Fac proteins for use in such methods, of preparing compositions for treating such disorders. |
| 05/20/2004 | US20040096448 Nucleic acid molecules encoding a protein interacting with ser/thr kinase akt |
| 05/20/2004 | US20040096447 Preventives/remedies for thickened scar, keloid or chronic arthritic diseases |
| 05/20/2004 | US20040096444 Identification of the endothelial receptor for the angiostatin kringle-5 |
| 05/20/2004 | US20040096443 Treatment of neurodegenerative diseases and conditions using par1 antagonists |
| 05/20/2004 | US20040096442 Modified anti-egfr antibodies with reduced immunogenicity |
| 05/20/2004 | US20040096438 Methods and compositions for the enhancement of wound healing |
| 05/20/2004 | US20040096437 Pharmaceutical composition comprising arginine deiminasa for inhibiting angio-genesis |
| 05/20/2004 | US20040096436 Method for treating cancer comprising administering to a subject in need of such treatment a therapeutically effective amount of a member selected from an inhibitor of a protein kinase, an enantiomer of such a compound, a prodrug of such a |
| 05/20/2004 | US20040096433 Alleviating hypertension associated with fetal malnutrition in utero, resulting in a post-natal condition known as fetal programming. Factors that lead to fetal programming can be used to predict development of conditions associated with |
| 05/20/2004 | US20040096431 Providing a tissue removal system; removing adipose tissue from a patient using the tissue removal system, the adipose tissue having a concentration of stem cells; processing at least a part of the adipose tissue to obtain a concentration |
| 05/20/2004 | US20040096429 Method for producing cytotoxic T-cells |
| 05/20/2004 | US20040096426 Compositions and methods for identifying antigens which elicit an immune response |
| 05/20/2004 | US20040096425 Method for introducing a molecule into the cytosol of a cell in which the cell is contacted with a photosensitising agent, the cell is irradiated with light of a wavelength effective to activate the photosensitising agent and, substantially at the |
| 05/20/2004 | US20040096403 Method for drug delivery to the pulmonary system |
| 05/20/2004 | US20040096401 Methods and compositions for the pulmonary delivery of insulin |
| 05/20/2004 | US20040096400 Methods and compositions for the pulmonary delivery insulin |
| 05/19/2004 | EP1420065A1 Process for producing inactivated virus envelope |
| 05/19/2004 | EP1420031A2 Bone morphogenetic protein (BMP)-18 compositions |
| 05/19/2004 | EP1420010A1 Amphoteric lipid compound and use thereof |
| 05/19/2004 | EP1419783A2 Use of a composition comprising an exendin or a compound derived therefrom and a pharmaceutical carrier |
| 05/19/2004 | EP1419782A1 Use of consensus interferon for reducing the side-effects of interferon treatment in viral hepatitis |
| 05/19/2004 | EP1419780A1 Use of docosahexaenoic acid for the manufacture of a medicament for the treatment of senile dementia and Alzheimer's disease |
| 05/19/2004 | EP1419778A1 Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds |
| 05/19/2004 | EP1419764A1 Use of an association of synergic calcium channel blocker agents for preventing or treating wrinkles and fine lines |
| 05/19/2004 | EP1419428A2 Ensemble-based strategy for the design of protein pharmaceuticals |
| 05/19/2004 | EP1419393A1 Tumor specific oligosaccharide sequences and use thereof |
| 05/19/2004 | EP1419276A2 Diagnosis and treatment of diseases associated with altered expression of hipk1 |
| 05/19/2004 | EP1419267A2 Methods and means of histone methylation |
| 05/19/2004 | EP1419264A2 Kinases and phosphatases |
| 05/19/2004 | EP1419257A1 Methylation resistant vectors |
| 05/19/2004 | EP1419256A2 Conjugates for the modulation of immune responses |
| 05/19/2004 | EP1419252A2 Genetic analysis of peyers's patches and m cells and methods and compositions targeting peyer's patches and m cell receptors |
| 05/19/2004 | EP1419249A2 TIMM8b-RELATED PROTEIN |
| 05/19/2004 | EP1419242A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 05/19/2004 | EP1419241A2 Improved nitroreductase enzymes |
| 05/19/2004 | EP1419239A1 Mullerian inhibiting substance levels and ovarian response |
| 05/19/2004 | EP1419236A2 Methods for treating or preventing sclerotic disorders using cd2-binding agents |
| 05/19/2004 | EP1419178A1 Somatostatin analogues and their use somatostatin analogues binding to all somatostatin receptor and their use |
| 05/19/2004 | EP1419177A2 A purification process for large scale production of gc-globulin, product obtained thereby and their use in medicine |
| 05/19/2004 | EP1419176A2 Glycoconjugates of sialic acid derivates, methods for their production and use thereof |
| 05/19/2004 | EP1419175A2 Replikin peptides and uses thereof |
| 05/19/2004 | EP1419174A2 Process for preparing glycopeptide derivatives |
| 05/19/2004 | EP1419173A2 Peptides that bind to atherosclerotic lesions |
| 05/19/2004 | EP1419169A1 Antisense modulation of corest expression |
| 05/19/2004 | EP1419168A2 Antisense modulation of apolipoprotein b expression |
| 05/19/2004 | EP1419129A2 Use of branched-chain fatty acids and derivatives thereof for the treatment of pain |
| 05/19/2004 | EP1418938A1 Bont/e or snap-25e for treating botulinum toxin a or c1 poisoning and inhibiting muscle contraction |
| 05/19/2004 | EP1418937A2 Enhancing organ maturity in neonates and predicting their duration of intensive care |
| 05/19/2004 | EP1418936A2 Pharmaceutical compositions for preventing or treating th1 and th2 cell related diseases by modulating the th1/th2 ratio. |
| 05/19/2004 | EP1418935A1 Genobix agonists and antagonists for use in the treatment of metabolic disorders |
| 05/19/2004 | EP1418934A1 Xobesin agonists and antagonists for the treatment of metabolic disorders |
| 05/19/2004 | EP1418933A2 Process for preparing glycopeptide phosphonate derivatives |
| 05/19/2004 | EP1418932A1 An anti-angiogenic state in mice and humans with retinal photorecptor cell degeneration |
| 05/19/2004 | EP1418931A1 New drug |
| 05/19/2004 | EP1418930A2 Mucosal repair by tff2 peptides |
| 05/19/2004 | EP1418926A2 Compositions comprising bone marrow cells together with demineralized and/or mineralized bone matrix and their use in bone marrow transplantation |
| 05/19/2004 | EP1418922A1 Compositions comprising negatively charched phospholipids for treatment and/or prevention of macular degeneration and method for its manufacture |
| 05/19/2004 | EP1418920A1 As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness |
| 05/19/2004 | EP1418893A1 Compositions and techniques for localized therapy of restenosis |
| 05/19/2004 | EP1418890A1 Propellant-based microparticle formulations |
| 05/19/2004 | EP1418889A2 Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds |
| 05/19/2004 | EP1418813A2 Methods, compositions and kits relating to chitinases and chitinase-like molecules and inflammatory disease |
| 05/19/2004 | EP1418810A1 Oral treatment of hemophilia |
| 05/19/2004 | EP1339377A4 Use of cyclosporin 7-thioamide derivatives for hair growth |
| 05/19/2004 | EP1304116A4 New class of bioactive glycoprotein |
| 05/19/2004 | EP1107982B1 Reversible boron complexes of 1,2-(cis)-diol cyclic peptides |
| 05/19/2004 | EP1082137A4 REVERSAL OF PROINFLAMMATORY RESPONSE BY LIGATING THE MACROPHAGE Fc$g(g)RI RECEPTOR |
| 05/19/2004 | EP1037927B1 Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
| 05/19/2004 | EP1021553B1 Eukaryotic gene expression cassette and uses thereof |
| 05/19/2004 | EP1017810B1 Agonist and antagonist peptides of carcinoembryonic antigen (cea) |
| 05/19/2004 | EP1000051B1 Carbamyloxy compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 05/19/2004 | EP0960123A4 Sprouty protein and coding sequence |
| 05/19/2004 | EP0870026B1 Ob protein derivatives having prolonged half-life |
| 05/19/2004 | EP0801572B1 Composition for inhibiting intimal hyperplasia using pdgf antagonists and heparin |
| 05/19/2004 | EP0787190B1 Hepatitis e virus antigens and uses therefor |